Tracking Louisiana Newborn Screening Conditions

Louisiana’s Newborn Screening Program screens for many different genetic and metabolic disorders through the heel stick screening. All states and territories have a newborn screening program to ensure screening occurs within the first 24-48 hours after birth and that appropriate follow-up education, testing, and care are provided. As medical technologies and treatments advance, it becomes possible to screen for more conditions. Therefore, the National Advisory Committee on Heritable Disorders in Newborns and Children was established to provide advice and recommendations to the Secretary of Health and Human Services (HHS Secretary) on what conditions should be included on a Recommended Uniform Screening Panel. Some states rely on the Recommended Uniform Screening Panel to inform their own state panels.

Additionally, each state defines its own processes for adding conditions. In Louisiana, the conditions on the state newborn screening panel and the laboratories authorized to complete the testing are outlined in the Louisiana Administrative Code40.v.6303. As of February 2024, Louisiana’s standard newborn screening panel approved in the Louisiana Administrative Code 40 includes 34 of the 37 conditions listed in the Recommended Uniform Screening Panel. The procedure for adding new conditions to the Louisiana Newborn Screening Panel is outlined below.

Procedure for Adding New Conditions to the Louisiana Newborn Screening Panel

  1. Panel Adds Screening:

    • The National Advisory Committee on Heritable Disorders in Newborns and Children recommends the condition for addition to the Recommended Uniform Screening Panel.

    • The Secretary of Health and Human Services approves the condition for inclusion in the Recommended Uniform Screening Panel.

  2. Review by the Advisory Committee:

    • The Louisiana Genetic Diseases Advisory Committee meets quarterly to review the science and cost-benefit of adding new conditions.

    • Consideration to add the condition is given to the testing methodology, treatment, and cost.

  3. Leadership Advancement:

    • The Genetic Diseases Program shares the Genetic Diseases Program Advisory Committee’s recommendations with the Surgeon General and leadership at the Office of Public Health and the Louisiana Department of Health for review and approval.

    • The laboratory prepares for pilots and validations.

    • The Genetic Diseases Program initiates preparation for follow-up systems.

  4. Legislative Advancement:

    • The department initiates rulemaking for adding the condition to the Newborn Screening Rule (LAC 48.v.6303).

    • The department initiates a request for budget appropriation (if applicable).

  5. Implement:

    • The Genetic Diseases Program finalizes the process for reporting and follow-up.

    • The laboratory completes validation studies and secures external laboratory support, if needed.

    • Communicate with healthcare providers, systems, advocates, and other constituencies.

    • Testing “goes live” once the updated rule is promulgated.

 

List of Conditions in the Process of Being Added to the Louisiana Newborn Screening Panel

Updated as of October 2025

 

Condition Date Added to the RUSP Current Procedure Stage
X-Linked Adrenoleukodystrophy Note: study ordered by SCR 3 of the 2016 Regular Session (not promulgated, not tested for) 2015 5. Implementation from the lab
Guanidinoacetate Methyltransferase Deficiency 2022 2. Review by Genetic Diseases Program Advisory Committee
Mucopolysaccharidosis Type II  2022 2. Review by Genetic Diseases Program Advisory Committee
Krabbe Disease
Note: study ordered by Act 507 of the 2016 Regular Session
2024 1. Recommended Uniform Screening Panel adds screening

 

List of Conditions Currently on the Louisiana Newborn Screening Panel

Learn more about each condition by visiting the Newborn Screening Panel webpage.

 

Condition Date Added to the Recommended Uniform Screening Panel Date Added to the Louisiana Newborn Screening Panel
Classic Phenylketonuria Pre-dates Recommended Uniform Screening Panel 1964, Act 269
Primary Congenital Hypothyroidism Pre-dates Recommended Uniform Screening Panel 1978
Tyrosinemia, Type I Pre-dates Recommended Uniform Screening Panel 2006
S,S Disease (Sickle Cell Anemia) Pre-dates Recommended Uniform Screening Panel 1972 for Af.Am., 1992 for all
Classic Galactosemia Pre-dates Recommended Uniform Screening Panel 1981  
S, βeta-Thalassemia Pre-dates Recommended Uniform Screening Panel 1992
S,C Disease (“mild” form of sickle cell anemia) Pre-dates Recommended Uniform Screening Panel 1992
Biotinidase Deficiency Pre-dates Recommended Uniform Screening Panel 1999, Act 328
Congenital adrenal hyperplasia Pre-dates Recommended Uniform Screening Panel 2006
Cystic Fibrosis Pre-dates Recommended Uniform Screening Panel 2007
Homocystinuria Pre-dates Recommended Uniform Screening Panel 1981, added to the rule in 2006
Maple Syrup Urine Disease 2006 1981, added to the rule in 2006
Propionic Acidemia 2006 2006
Methylmalonic Acidemia (methylmalonyl-CoA mutase) 2006 2006
Methylmalonic Acidemia (Cobalamin disorders) 2006 2006
Isovaleric Acidemia 2006 2006
3-Methylcrotonyl-CoA Carboxylase Deficiency 2006 2006
3-Hydroxy-3-Methyglutaric Aciduria 2006 2006
Holocarboxylase Synthase Deficiency 2006 2006
ß-Ketothiolase Deficiency 2006 2006
Glutaric Acidemia Type I 2006 2006
Carnitine Uptake Defect/Carnitine Transport Defect 2006 2006
Medium-chain Acyl-CoA Dehydrogenase Deficiency 2006 2006
Very Long-chain Acyl-CoA Dehydrogenase Deficiency 2006 2006
Long-chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency 2006 2006
Trifunctional Protein Deficiency 2006 2006
Argininosuccinic Aciduria 2006 2006
Citrullinemia, Type I 2006 2006
Severe Combined Immunodeficiency 2009 2018
Pompe Disease 2013 2021 Regular Session, Act 305 (implemented January 1, 2022)
Mucopolysaccharidosis Type I 2015 2021 Regular Session, Act 305 (implemented January 1, 2022)
Spinal Muscular Atrophy 2018 2021 Regular Session, Act 305 (implemented January 1, 2022)

 

Please submit questions about the Louisiana Newborn Screening Panel through this form or email [email protected].

Surgeon General Ralph L. Abraham, M.D.

Secretary Bruce D. Greenstein

Powered by Cicero Government